speb/financial-data huggingface dataset:
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 9291000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 934012000.00
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 466179000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Other Payable: 306504000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 306504000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Other Properties: 800858000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 800858000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 220589000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 220589000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 226588000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 226588000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Other Special Charges: -3697000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Payables: 2228296000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Payables: 2228296000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 24335000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 24335000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 145917000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 145917000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Pretax Income: 762458000.00
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 244752000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
APCOTEXIND.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 12531000.00
APCOTEXIND.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -300086000.00
APCOTEXIND.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -499520000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 932317000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 932317000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 10363396000.00
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 2435015000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 415771000.00
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 105287000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 2146000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 2146000.00
APCOTEXIND.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -312500000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 124977000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 124977000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 4543212000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 4543212000.00
APCOTEXIND.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 413419000.00
APCOTEXIND.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 86287000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 516468000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 615205000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Share Issued: 51844960.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 51844960.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Special Income Charges: 3697000.00
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 5531837000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 5531837000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 5528017000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 5528017000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 5718221.30
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Tax Provision: 221812000.00
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 77202000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.29
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.32
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 181814000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 181814000.00
APCOTEXIND.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -192743000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Total Assets: 9988529000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 9988529000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 6155419000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 6155419000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Total Debt: 1893381000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 1893381000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 5531837000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 5531837000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Total Expenses: 12943426000.00
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 3214661000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 4456692000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 4456692000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 4904775000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 4904775000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 948580000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 948580000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 11075000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 19922000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 19922000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 19657000.00
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 19657000.00
APCOTEXIND.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Work In Process: 22046000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 22046000.00
APCOTEXIND.NS balance_sheet (annual, 2025-03-31) — Working Capital: 1575642000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 1575642000.00
APCOTEXIND.NS income_statement (annual, 2025-03-31) — Write Off: 0.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 712792000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 3757641000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 51782162.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 3.70
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 2771423000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 112629000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 112629000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 51782162.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 3.70
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 191594000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — EBIT: 299862000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — EBITDA: 412491000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 986218000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 36528000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 36528000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Net Income: 191594000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 191594000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 191594000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 191594000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 191594000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 191594000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -36528000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -36528000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 412491000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 191594000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Operating Income: 273426000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 3757641000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 26436000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 407631000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 263334000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 2771423000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 112629000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 71740000.00
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.27
APCOTEXIND.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 3484215000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 746539000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 3366931000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 1539411000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 2056231000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Assets Held For Sale Current: 0.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 883074000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 51836270.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 4.88
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 40019000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 103690000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 267119000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 809796000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 103690000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 5798987000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 77191000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 2334535000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 4505224000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 11618000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 842500000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 854118000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 2790965000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 35867000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 120159000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 120159000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 51836270.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 4.88
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 252961000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — EBIT: 389403000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — EBITDA: 509562000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 2856000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 3904518000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 1032396000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 29608000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 29608000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 1330805000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 7109056000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Investment Properties: 14303000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 883074000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 28401000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 467569000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 495970000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 36470000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 1042950000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Net Income: 252961000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 252961000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 252961000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 252961000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 252961000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 252961000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -29608000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -29608000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 3904518000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 5796131000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 235725000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 452062000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 212534486.29
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Operating Income: 285857000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 3366931000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 51844960.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 304018000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 113295000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 5695297000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 97484000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 46046000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 420212000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 3827327000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Other Receivables: 4374000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 542677000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Payables: 1552741000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 359795000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 2334535000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 120159000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 51844960.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 57500000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 5798987000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 5796131000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 17073486.29
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 106834000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.30
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 0.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 9407459000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 6266556000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 1350088000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 5798987000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 3081074000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 3608472000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 4902235000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 817507000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 13330000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 57500000.00
APCOTEXIND.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 57500000.00
APCOTEXIND.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 1714259000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 718523000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 3314578000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 51904907.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 4.28
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 2283419000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 122685000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 122685000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 51904907.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 4.28
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 222153000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — EBIT: 297525000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — EBITDA: 420210000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 1031159000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 22032000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 22032000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Net Income: 222153000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 222153000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 222153000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 222153000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 222153000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 222153000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -22032000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -22032000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 468056000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 260735223.28
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Operating Income: 312636000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 3314578000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 32735000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 396315000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Other Special Charges: 47846000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 275493000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 2283419000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 122685000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -47846000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -9263776.72
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 53340000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.19
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 3001942000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -47846000.00
APCOTEXIND.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -47846000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — +Operating Expense: 2956675000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 1059683000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — +Total Revenue: 14268400000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 3975838000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 1844528000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 1844528000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 2444877000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 2444877000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -1893819000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -1893819000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Additional Paid In Capital: 260027000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 260027000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -54989000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -54989000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Amortization: 2152000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Amortization Cash Flow: 2152000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Assets Held For Sale Current: 13852000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 13852000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 949056000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 949056000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 51844960.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 51851642.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Basic EPS: 19.56
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 6.70
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 491403000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 964186000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 964186000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -444727000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 34326000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 34326000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 103690000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 103690000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 318330000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 318330000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 543499000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 543499000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -361796000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Cash Financial: 318330000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Cash Financial: 318330000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Change In Inventory: 95907000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -119847000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 76167000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Change In Payable: 328218000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Change In Receivables: 87441000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: 467886000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 51455000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Common Stock: 103690000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 103690000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 6209894000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 6209894000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 112650000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 112650000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 9972829000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 2509564000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Current Assets: 4953869000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 4953869000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 12697000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 12697000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Current Debt: 613074000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 613074000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 625771000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 625771000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 2980991000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 2980991000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 100418000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 100418000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Depreciation: 493447000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 495599000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 495598000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 140127000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 493446000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 140127000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 51844960.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 51851642.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Diluted EPS: 19.56
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 6.70
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 1014113000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 347406000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Dividends Payable: 26544000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 26544000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 4737000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — EBIT: 1446739000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — EBIT: 473803000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — EBITDA: 1942338000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — EBITDA: 613930000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — End Cash Position: 542858000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -1408878000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 360978000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 360978000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 1589656000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -19249000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 116995000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 1882000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 1882000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 2499866000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 2499866000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 5629045000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 5629045000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Gross Profit: 4295571000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 1466274000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Interest Expense: 98246000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 23932000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 98246000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 23932000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Interest Income: 23283000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Interest Income Non Operating: 23283000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -111617000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 23744000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Inventory: 1281847000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 1281847000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 7139492000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 7139492000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -574050000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Investment Properties: 14141000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Investment Properties: 14141000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 949056000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 949056000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Land And Improvements: 95048000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 95048000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 21629000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 21629000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 316524000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 316524000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 338153000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 338153000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -313066000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 117704000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 117704000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Machinery Furniture Equipment: 3569263000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 3569263000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Net Debt: 611268000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 611268000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -13529000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Net Income: 1014113000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Net Income: 347406000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 1014113000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 347406000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 1014113000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 347406000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 1014113000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 347406000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 1014113000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 347406000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 1348493000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 1014113000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 347406000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Net Interest Income: -88817000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -23932000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -224593000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: -924301000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: -313066000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -88817000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -23932000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: 4166000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Net PPE: 3735226000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 3735226000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -382104000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: -611235000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 6208012000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 6208012000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 174718000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 174718000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 117704000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 117704000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 189902000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 189902000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 1957897000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 613930000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Normalized Income: 1025581538.90
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 347406000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 2034383000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Operating Income: 1338896000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Operating Income: 406591000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Operating Revenue: 14268400000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 3975838000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 51844960.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 51844960.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 350070000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 350070000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 2101000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 2101000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 6106204000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 6106204000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 1882000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 1882000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Other Inventories: 23526000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Other Inventories: 23526000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 84651000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: -36000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: -36000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 10910000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 67212000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 978696000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 552780000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Other Payable: 345261000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 345261000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Other Properties: 887898000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 887898000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 198795000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 198795000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 225169000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 225169000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Other Special Charges: -12398000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Payables: 2231375000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Payables: 2231375000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 100418000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 100418000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 123454000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 123454000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Pretax Income: 1348493000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 449871000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Properties: 0.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 13444000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -569388000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -444727000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Raw Materials: 838179000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Raw Materials: 838179000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 9972829000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 2509564000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 495599000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 140127000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Rent And Landing Fees: 4327000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 4327000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -313066000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 141363000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 141363000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Retained Earnings: 5249131000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 5249131000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 344795000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 62623000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 523148000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 640143000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Share Issued: 51844960.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 51844960.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Special Income Charges: -27889000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 6209894000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 6209894000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 6208012000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 6208012000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -4090461.10
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Tax Provision: 334380000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 102465000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.26
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.23
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 206182000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 206182000.00
APCOTEXIND.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -342912000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Total Assets: 9864873000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 9864873000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 6526418000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 6526418000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Total Debt: 963924000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 963924000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 6209894000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 6209894000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Total Expenses: 12929504000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 3569247000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 3654979000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 3654979000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 4911004000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 4911004000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 673988000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 673988000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Total Other Finance Cost: 13854000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 15042000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 15042000.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -15559000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
APCOTEXIND.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -15559000.00
APCOTEXIND.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Work In Process: 59164000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Work In Process: 59164000.00
APCOTEXIND.NS balance_sheet (annual, 2026-03-31) — Working Capital: 1972878000.00
APCOTEXIND.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 1972878000.00